Inventiva (IVA) Long-Term Debt Repayments (2019 - 2025)
Inventiva (IVA) posted quarterly Long-Term Debt Repayments of -$2.0 million for Q2 2025, down 59.95% year-over-year from -$5.1 million in Q2 2024, and down 5.93% quarter-over-quarter from -$1.9 million in Q4 2024.
Inventiva (IVA) Long-Term Debt Repayments (2019 - 2025) Analysis & Trends
Inventiva's Long-Term Debt Repayments history runs 6 years deep, the most recent figure standing at -$2.0 million for Q2 2025.
- In Q2 2025, Long-Term Debt Repayments fell 59.95% year-over-year to -$2.0 million; the TTM figure through Jun 2025 stood at -$3.3 million (down 154.98% YoY), while the FY2024 annual figure was -$1.9 million, up 28.42% from the prior year.
- Long-Term Debt Repayments for Q2 2025 stood at -$2.0 million, down from -$1.9 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was -$14871.6 in Q4 2021, with the low at -$2.7 million in Q4 2023.
- The 4-year median for Long-Term Debt Repayments is -$1.6 million (2023), against an average of -$1.4 million.
- The sharpest annual moves came in 2021 and 2025: Long-Term Debt Repayments surged 74.01% in 2021, then tumbled 59.95% in 2025.
- Inventiva's Long-Term Debt Repayments stood at -$14871.6 in 2021, then tumbled by 17878.61% to -$2.7 million in 2023, then rose by 28.42% to -$1.9 million in 2024, then dropped by 5.93% to -$2.0 million in 2025.
- Business Quant data shows IVA's Long-Term Debt Repayments at -$2.0 million in Q2 2025, -$1.9 million in Q4 2024, and -$1.3 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 17.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Inventiva | 888.89 Mn | 888.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2.03 Mn |
| Jun 30, 2025 | -2.03 Mn |
| Dec 31, 2024 | -1.91 Mn |
| Dec 31, 2024 | -1.91 Mn |
| Jun 30, 2024 | -1.27 Mn |
| Jun 30, 2024 | -1.27 Mn |
| Dec 31, 2023 | -2.67 Mn |
| Dec 31, 2023 | -2.67 Mn |
| Jun 30, 2023 | -1.58 Mn |
| Jun 30, 2023 | -1.58 Mn |
| Dec 31, 2021 | -14,871.62 |
| Dec 31, 2021 | -14,871.62 |
| Mar 31, 2021 | -15,681.07 |
| Mar 31, 2021 | -15,681.07 |
| Dec 31, 2020 | -57,229.91 |
| Dec 31, 2020 | -57,229.91 |
| Jun 30, 2020 | -15,420.44 |
| Jun 30, 2020 | -15,420.44 |
| Mar 31, 2020 | -37,533.93 |
| Mar 31, 2020 | -37,533.93 |